Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (8094)	12/20/1998 8:43:00 AM
From: Robert K.	Read Replies (1) \| Respond to of 17367

Does your recent discovery put you a few years ahead of the curve or are you a few years behind the curve? VBG

To: Tharos who wrote (8094)	12/20/1998 5:16:00 PM
From: aknahow	Respond to of 17367

Of interest re sepsis and resistance. Convergent evolution of antibiotic resistance Use of extended-spectrum cephalosporins has led to the selection of Gram-negative bacteria that are resistant to these agents through the action of enzymes that destroy their activity known as beta-lactamases. A gene that encodes one such enzyme, TEM-26, has been characterized in clinical isolates of Klebsiella pneumoniae and Escherichia coli derived from patients on the Paediatric Oncology Unit of St James' University Hospital, Leeds. This Leeds beta-lactamase gene differs at six positions from the sequence of the first TEM-26 gene described in Stanford, California, USA. The evolution of antibiotic resistance genes in two different geographical locations suggests that the extended-spectrum beta-lactamase activity can evolve via different routes. "This has serious implications for the treatment of Gram-negative sepsis in a vulnerable patient group" said Dr. John Heritage one of group involved in this work. L.C.F. Hibbert-Rogers, J. Heritage, N. Todd,& and P.M. Hawkey. 1994 Journal of Antimicrobial Chemotherapy 33:707-20 ALSO: users.vnet.net